Aprea-Cuccaro clan

Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, November 9, 2023
HERG, Synthetic lethality, DDR, Acquisition, Safety, MD Anderson Cancer Center, WEE1, Therapy, University, PLK3, Gynecologic oncology, IND, ATR, PLK, Patient, PLK1, Division, FDA, Conference, Cardiotoxicity, Cell death, Ovarian cancer, APRE, Anemia, Poster, KOL, PLK2, AACR, Pharmaceutical industry, Aprea-Cuccaro clan

DOYLESTOWN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the three and nine months ended September 30, 2023, and provided a business update.

Key Points: 
  • DOYLESTOWN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the three and nine months ended September 30, 2023, and provided a business update.
  • “We are very pleased by the progress of our diversified programs this past quarter.
  • “We are continuing with patients in the dose escalation portion of the study, and the dose expansion cohort is on track to be initiated in 2Q 2024.
  • The first poster included initial data from the Company’s first-in-human Phase 1/2a dose escalation trial of ATRN-119 in solid tumors.

Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways

Retrieved on: 
Tuesday, October 24, 2023
Aprea-Cuccaro clan, IND, DDR, APRE, WEE1, MD Anderson Cancer Center, Ataxia–telangiectasia, University of Pennsylvania, News, KOL, Perelman School of Medicine at the University of Pennsylvania, University, Therapy, ATR, Patient, Pharmaceutical industry

DOYLESTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced it will host a KOL event on Tuesday, October 31, 2023 at 11:00 am ET.

Key Points: 
  • DOYLESTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced it will host a KOL event on Tuesday, October 31, 2023 at 11:00 am ET.
  • The Aprea Therapeutics team will discuss the Phase 1/2a study evaluating its lead program of a highly potent and selective macrocyclic inhibitor of ataxia telangiectasia and Rad3-related (ATR), ATRN-119, in patients with advanced solid tumors having mutations in defined DDR genes.
  • The session will be available for replay on the News and Events portion of the Investor Relations section of the company’s website.
  • To register for the event, please click here .

Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Tuesday, September 19, 2023
Aprea-Cuccaro clan, WEE1, APRE, Cancer, AACR, Therapy, IND, Conference, ATR, Pharmaceutical industry

DOYLESTOWN, Pa., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced two poster presentations at the upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held on October 11-15, 2023, in Boston, MA.

Key Points: 
  • DOYLESTOWN, Pa., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced two poster presentations at the upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held on October 11-15, 2023, in Boston, MA.
  • Aprea is in development with two assets.
  • Its lead program is ATRN-119, a clinical-stage small-molecule ATR inhibitor being developed for solid tumor indications.
  • Details of the poster presentations are as follows:

Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors

Retrieved on: 
Monday, September 11, 2023
APRE, KOL, CDX, Neoplasm, PLK, Platinum, PLK1, WEE1, PLK2, Cell cycle, AUC, CCNE1, Aprea-Cuccaro clan, Growth, PLK3, Ovarian cancer, Therapy, Family, Safety, Pharmaceutical industry

DOYLESTOWN, Pa., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced updated preclinical data supporting development of the Company’s WEE1 inhibitor candidate, ATRN-1051, for the treatment of ovarian cancer.

Key Points: 
  • The preclinical and in vitro data suggest that the selective properties of ATRN-1051 may make it a more efficacious cancer therapy than the other WEE1 inhibitors in development.
  • Such off-targeting of the PLK family has been a challenge to other WEE1 inhibitors in the class.
  • Evidence generated by Aprea suggests that off-target inhibition of PLK1 substantially limits the ability of WEE1 inhibitors to cause genotoxicity, the proposed mechanism by which WEE1 inhibitors act as cancer therapeutics.
  • In addition to the anti-tumor activity, the preclinical studies of ATRN-1051 indicate improved AUC pharmacokinetic properties compared to other WEE1 inhibitors, with the low dose of ATRN-1051 showing a similar AUC as higher doses of other WEE1 inhibitors.

Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman

Retrieved on: 
Thursday, August 24, 2023
PTCL, APRE, Pitié-Salpêtrière Hospital, Therapy, Oxford, Oxaliplatin, United States Air Force Scientific Advisory Board, American Society of Pediatric Hematology/Oncology, DNA, EORTC, National Cancer Institute, Acquisition, Treatment, European Organization of Supreme Audit Institutions, Sanofi, Rhône-Poulenc, Mathematics, Compensated emancipation, Medical device, Management, Cancer, Celgene, Aprea-Cuccaro clan, Research

Dr. Bizzari will replace Mr. Christian Schade, who is stepping down from the Board.

Key Points: 
  • Dr. Bizzari will replace Mr. Christian Schade, who is stepping down from the Board.
  • “We warmly welcome Dr. Jean-Pierre Bizzari to our Board of Directors.
  • “Jean-Pierre joins our Board as Chris Schade retires from his role as Chairman and member of the Board to focus on his other commitments.
  • Dr. Richard Peters has served as independent Director of Aprea since June 2020 and Chair of the Compensation Committee since November 2020.

Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations

Retrieved on: 
Thursday, August 10, 2023
Insurance, APRE, DNA, IPR, Pharmacia, DDR, Renã A. S. Robinson, Drug discovery, Clinical trial, Pharmacokinetics, G&A, Research, WEE1, Research and development, DNA replication, Acquisition, DNA repair, Novartis, Administration, Cell cycle, R, Sanofi, Therapy, Safety, IND, ATR, Mammography, Fine chemical, Pharmaceutical industry, Cryptocurrency, Life insurance, Aprea-Cuccaro clan, Pfizer

DOYLESTOWN, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the three and six months ended June 30, 2023 and provided a business update.

Key Points: 
  • DOYLESTOWN, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the three and six months ended June 30, 2023 and provided a business update.
  • The Company expects to report initial interim safety, tolerability, and pharmacokinetic data from the ongoing Phase 1 trial of ATRN-119 in the fourth quarter of 2023.
  • Select Financial Results for the Second Quarter ended June 30, 2023
    As of June 30, 2023, the Company reported cash and cash equivalents of $27.7 million.
  • General and Administrative (G&A) expenses were $1.7 million for the quarter ended June 30, 2023, compared to $15.6 million for the same period in 2022.

Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations

Retrieved on: 
Monday, May 15, 2023
Insurance, APRE, DNA, AACR, Therapy, Pharmacia, DDR, Drug discovery, Survival, Clinical trial, American Association for Cancer Research, Pharmacokinetics, Woman, G&A, Research, Biomarker, WEE1, Research and development, DNA replication, Death, ATRN, DNA repair, Novartis, Patient, Administration, Cell cycle, Annual general meeting, Poster, R, Sanofi, NCI, Safety, IND, ATR, Mammography, PARP, Conference, Pharmaceutical industry, Life insurance, Aprea-Cuccaro clan, Pfizer

DOYLESTOWN, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today reported financial results for the three months ended March 31, 2023 and provided a business update.

Key Points: 
  • DOYLESTOWN, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today reported financial results for the three months ended March 31, 2023 and provided a business update.
  • Presented Preclinical data on pipeline programs at the American Association for Cancer Research (AACR) 2023 Annual Meeting, held April 14-19, 2023, in Orlando, Florida.
  • Select Financial Results for the First Quarter ended March 31, 2023
    As of March 31, 2023, the Company reported cash and cash equivalents of $31.0 million.
  • General and Administrative (G&A) expenses were $3.4 million for the quarter ended March 31, 2023, compared to $4.0 million for the same period in 2022.

Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors

Retrieved on: 
Monday, May 8, 2023
APRE, DNA, Drug development, Therapy, Pharmacia, DDR, Research, Mammography, Novartis, Patient, Maas, Cancer, Hematology, Paris Descartes University, Principal, Sanofi, Independent Board for Presbyterian Foreign Missions, Pharmaceutical industry, Aprea-Cuccaro clan, Pfizer

DOYLESTOWN, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced the appointment of Gabriela Gruia, M.D.

Key Points: 
  • DOYLESTOWN, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced the appointment of Gabriela Gruia, M.D.
  • to its Board of Directors, effective as of May 5, 2023.
  • Dr. Gruia joins Aprea with over 25 years of clinical, regulatory and life science leadership experience.
  • She also serves as an Independent Board Director at Tessa Therapeutics, TScan Therapeutics, and Molecular Templates.

Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations

Retrieved on: 
Thursday, March 30, 2023
Acceleration, APRE, DNA, AACR, Therapy, DDR, SBIR, Survival, Clinical trial, Pharmacokinetics, American Association for Cancer Research, Woman, Research, Biomarker, WEE1, Research and development, National Cancer Institute, Death, Acquisition, DNA repair, Patient, Administration, Cell cycle, Annual general meeting, Poster, R, FDA, NCI, IND, ATR, Pharmaceutical industry, Cryptocurrency, Life insurance, Aprea-Cuccaro clan

“2022 has been another transformational year for Aprea with progress on multiple fronts,” said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea.

Key Points: 
  • “2022 has been another transformational year for Aprea with progress on multiple fronts,” said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea.
  • Additionally, we announced a non-dilutive SBIR award from the National Cancer Institute and welcomed John Hamill to the Aprea team.
  • Select Financial Results for the Fourth Quarter ended December 31, 2022
    As of December 31, 2022, the Company reported cash and cash equivalents of $28.8 million.
  • Research and Development (R&D) expenses were $0.5 million for the quarter ended December 31, 2022, compared to $4.5 million for the fourth quarter of 2021.

Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock

Retrieved on: 
Monday, February 27, 2023
Telephone, Therapy, DNA, Prospectus, Form, DDR, Park Avenue, SEC filing, APRE, Attention, Form S-3, Sale, Aprea-Cuccaro clan, Security (finance)

DOYLESTOWN, Pa., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced the closing of its previously announced underwritten public offering of 1,050,000 shares of its common stock at a public offering price of $5.25 per share.

Key Points: 
  • DOYLESTOWN, Pa., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced the closing of its previously announced underwritten public offering of 1,050,000 shares of its common stock at a public offering price of $5.25 per share.
  • Gross proceeds from the offering before deducting underwriting discounts and commissions and offering expenses are approximately $5.5 million.
  • In addition, Aprea has granted the underwriter a 30-day option to purchase up to an additional 157,500 shares of common stock.
  • The public offering was made pursuant to an effective shelf registration statement on Form S-3, as amended (File No.